Ngoc-Quynh-Nhu Nguyen

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index847citations32works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(13), Cancer, Hypoxia, and Metabolism(12), Growth Hormone and Insulin-like Growth Factors(8), Cardiovascular Issues in Pregnancy(5), Blood Coagulation and Thrombosis Mechanisms(4)

Publications32 total

The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis
Science Signaling·2015· 54 citedOpen Access
Erratum: Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin
Nature Medicine·2015· 2 citedOpen Access
PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin
Nature Medicine·2014· 105 cited
PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin (vol 20, pg 741, 2014)
2014
MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy
Journal of Clinical Investigation·2013· 482 citedOpen Access
MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy
Open Repository and Bibliography (University of Liège)·2012
MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy
Open Repository and Bibliography (University of Liège)·2012
Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)·2012
MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy
Open Repository and Bibliography (University of Liège)·2012
Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)·2012
The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation
PLoS ONE·2011· 19 citedOpen Access
The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation
Open Repository and Bibliography (University of Liège)·2011
Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL
Open Repository and Bibliography (University of Liège)·2011
Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth
Cancer Letters·2009· 25 cited
The antiangiogenic factor 16K hPRL affects tumor vessel maturation
Open Repository and Bibliography (University of Liège)·2009
The contribution of vasculogenesis to tumor neovascularization after angiostatic treatment
Open Repository and Bibliography (University of Liège)·2009
Study of the effect of the antiangiogenic factor 16K hPRL in tumor vessel maturation
Open Repository and Bibliography (University of Liège)·2009
Evaluation of the ability of 16K hPRL to affect tumor vessel maturation
Open Repository and Bibliography (University of Liège)·2009
Inhibition of Tumor Growth and Metastasis Establishment by Adenovirus-mediated Gene Transfer Delivery of the Antiangiogenic Factor 16K hPRL
Molecular Therapy·2007· 34 citedOpen Access
Gene expression profiling of the antiangiogenic factor 16K human prolactin (hPRL) on endothelial cells underlines the key role of NF-κB and reveals novel mechanisms of action
9th European Congress of Endocrinology·2007
page 1 of 2Next →

Frequent Co-authors

Joseph Martial(32), Ingrid Struman(32), Sébastien P. Tabruyn(20), Agnès Noël(19), Michelle Lion(11), Karolien Castermans(9), Stéphanie Herkenne(9), Anne Cornet(9), Silvia Blacher(8), Khalid Bajou(7), Françoise Rentier‐Delrue(7), Ludovic Malvaux(6), Arjan W. Griffioen(5), Julie Halkein(4), Karen Sliwa(4), Denise Hilfiker‐Kleiner(4), Salvino D’Amico(4), Olivier Nivelles(4), Cécile Paques(4), Peter Carmeliet(4)